BioWorld Asia

June 6, 2007

Bavarian's Smallpox Vaccine Pact Worth Up To $1.6 Billion

Bavarian Nordic A/S could earn a total of $1.6 billion from its contract with the U.S. Department of Health and Human Services to supply a stockpile of next-generation safe smallpox vaccines. (BioWorld International) Read More

UK Ponders Plan Promoting Payment Upon Performance

Lost Copies Of Genes Dictate Risk Of Autoimmune Diseases

Soaring Interest In RNA Field Nets Exiqon $62.7 Million IPO

Evolutec Calling It Quits After Product Failure

Other News To Note

Pharmaxon Obtains Mimetic Peptide For Cell Mobility Drugs

Transgene In Line For €10M Milestone On CIN Compound

No Abstract Read More

Industry Rejoices at Fudged EU Advanced Therapies Agreement

ASCO Roundup

Today's news in brief

BioWorld

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

Illustration of Alzheimer's disease in the brain

ADPD 2026: Three inflection points to target Alzheimer’s disease

BioWorld Science

A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 17, 2026

SERCA inhibitor from Sumitomo shows promise for MSA-C treatment

BioWorld Science

At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, Sumitomo Pharma Co....